Proprietary Blend Supplements: Why Smart Buyers Avoid Them
Key Takeaways
- A proprietary blend names the ingredients in a mixture but not how much of each one is inside. The total weight appears on the panel. The doses do not.
- Proprietary blends are legal under federal labeling rules. They also make the panel hard to use. You cannot match what is in the bottle to what is in the research.
- Supplement effects depend on dose. An ingredient at the right amount may help. The same ingredient at a fraction of that amount may do nothing.
- "Pixie-dusting" is the industry term for adding a familiar ingredient at a token amount, mostly for label appeal. Underdosed supplements are hard to spot when the format hides the math.
- Supplement label transparency, where every ingredient and dose appears on the panel, is what lets a careful buyer judge a product on the evidence.
What Is a Proprietary Blend in Supplements?
A proprietary blend is a labeling format. It lets a supplement company group several ingredients into one line on the panel, list the total weight of the mixture, and keep each dose off the label. Federal labeling rules permit it. Proprietary blend supplements have been on shelves for decades. Most health-literate buyers have run into the format without noticing what it leaves off the panel.
Under 21 CFR § 101.36, the federal regulation governing nutrition labeling of dietary supplements, a company may group several ingredients into a single "proprietary blend" line on the Supplement Facts panel. (The Supplement Facts panel is the standard box that lists ingredients and amounts on a supplement label.) The ingredients inside the blend must be listed in descending order by weight, and the total weight of the blend must be on the panel. The dose of each one inside is not.
A concrete example helps. Picture a label that reads "Longevity Blend, 500 mg" followed by six ingredients in a column: trans-resveratrol, quercetin, alpha-lipoic acid, coenzyme Q10, lycopene, astaxanthin. The reader knows the blend weighs 500 mg in total. The reader knows trans-resveratrol weighs more than astaxanthin. The reader cannot tell whether the trans-resveratrol weighs 400 mg or 100 mg, and cannot tell whether the astaxanthin weighs 50 mg or 0.5 mg.
The regulation has been satisfied. The buyer has been told something. The link between the bottle and the published research is broken inside the blend.
The format is legal. The Food and Drug Administration's own labeling guide for dietary supplements confirms that a proprietary blend may appear on a panel exactly as described above. The practical question, for a buyer who wants to evaluate what is in the bottle, is how to read a panel that uses it.
Why Do Companies Use Proprietary Blend Supplements?
Companies that use proprietary blend supplements give three stated reasons and have one structural one. The stated reasons are protecting the recipe, standing apart from competitors, and keeping dose ratios private. The structural reason, the one the buyer feels most directly, is flexibility. A proprietary blend lets a company keep an expensive or high-profile ingredient prominent on the front of the bottle while quietly running it at a small dose inside.
Each stated reason can be legitimate. A formulator who has spent years tuning a specific ratio of compounds may have a real reason to keep that ratio off the panel. A brand may believe its blend is distinctive in a way that printing each dose would weaken. Both reasons can be real. The trade-off lands on the buyer, who loses the ability to compare what is on the label to what is in the research.
The structural reason is where the industry's term "pixie-dusting" comes in. Pixie-dusting means adding a recognizable, well-studied ingredient at a fraction of the dose used in the research that gave it its reputation. The ingredient appears on the label. The buyer knows the name. The amount, hidden inside a proprietary blend total, may be too small to do anything meaningful in the body.
The Federal Trade Commission has been clear about the substantiation standard, meaning the level of scientific proof a claim must meet, for supplement claims. The agency's 2022 Health Products Compliance Guidance says that claims about a supplement must be backed by competent and reliable scientific evidence for the product as marketed, including the actual dose. A claim built on the reputation of an ingredient that is present at a fraction of the studied dose does not meet that bar. Whether a company is making such a claim is hard to tell when the dose is undisclosed.
 |
The science: Federal rules require that any structure or function claim (a claim about how an ingredient affects a body system, distinct from a disease claim) made about a supplement be substantiated by competent and reliable scientific evidence for the product as marketed, at the dose actually present. The evidence: The U.S. Federal Trade Commission's 2022 Health Products Compliance Guidance states this standard explicitly and is the current FTC position on supplement claim substantiation. A supplement that includes a familiar ingredient at a token dose inside a proprietary blend cannot easily document that its dose meets the substantiation standard. |
ResilienZ-12 was built around the opposite practice. Every ingredient and its individual dose is printed on the Supplement Facts panel, so a buyer can match each amount to the published research instead of inferring it from a blend total. Where a blend leaves the substantiation question hard to answer, a fully disclosed panel turns it into a matter of reading the label.
A Quick Example of Pixie-Dusting
Take that hypothetical "Longevity Blend, 500 mg" again. Six ingredients inside, listed in descending order by weight. The first ingredient on the list, trans-resveratrol, could be anywhere from 100 mg to 450 mg. The sixth, astaxanthin, could be anywhere from milligrams down to micrograms.
The regulation has been followed. The format itself was chosen so the answer would not need to be on the label.
Without dose disclosure, the buyer cannot know any of the following from the panel alone:
- Whether the trans-resveratrol dose matches the dose used in the cardiovascular or longevity research that gave the ingredient its reputation.
- Whether the astaxanthin is present at a dose with any documented biological activity (any measurable effect in the body), or at a token amount included for label appeal.
- Whether the formula's six ingredients have been balanced against one another in any researched way, or simply combined to fill out a label.
The label is legally compliant. It is also the format a company chooses when it prefers not to specify. Underdosed supplements sit in exactly this gap.
Why Dose Matters in Proprietary Blend Supplements
Most supplement ingredients with credible research behind them have what scientists call a dose-response relationship. Too little produces no measurable effect. An appropriate range produces the studied effect. Too much can produce safety concerns. Proprietary blend dosing, by design, removes the part of the label that would let a buyer locate a product on that curve.
When a marketing statement reads "research shows X supports cardiovascular health," the research usually showed something more specific. The effect was measured at a particular dose, with a particular form of the ingredient, and over a defined duration. Strip those qualifiers out and the claim runs on familiarity with the ingredient and the assumption that the bottle holds enough of it.
Coenzyme Q10 (CoQ10) is a useful illustration. The U.S. National Center for Complementary and Integrative Health page on coenzyme Q10 summarizes the human research on CoQ10 across cardiovascular and other outcomes. The Q-SYMBIO trial, which established CoQ10's role in heart failure research, used a daily dose of 300 mg (100 mg three times daily). Many commercial supplements include CoQ10 at 30 mg as a label-appeal dose. A buyer who sees "CoQ10" inside an undisclosed proprietary blend dosing structure has no way to know which world the bottle is in.
Safety has its own dose curve. Safety ceilings are documented for fat-soluble vitamins, several minerals, and a number of botanicals (plant-based ingredients). U.S. supplement safety monitoring acts largely on adverse events after products reach the market. An adverse event is a reported case of harm linked to a supplement. A buyer taking the same ingredient in multiple products, where at least one of those is a proprietary blend, cannot add up the daily total.
Underdosed supplements are one risk of proprietary blend dosing. Inadvertent overdosing across a routine of multiple products is another.
A disclosed panel is what makes that arithmetic possible. Because ResilienZ-12™ prints the amount of each of its twelve active ingredients, a buyer who takes more than one product can add each ingredient into a daily total and see where it sits against documented safety ceilings.
In plain terms: A supplement ingredient has to be in the bottle in real amounts to work. The studies show what those amounts are. When the label hides the dose, the link to the science breaks.
Each dose printed on the panel is a small contract with the careful buyer.
Why Avoid Proprietary Blends in Supplements
Verifiability, the ability to match what is in the bottle to what the published research describes, is the central reason a careful buyer avoids proprietary blend supplements. Some brands use proprietary blends and still formulate well. The format itself is not categorical proof of malpractice. What proprietary blend dosing removes, in every case, is the buyer's ability to reason from the published science to the bottle on the shelf.
Verifiability matters in four ways for a careful buyer.
- Comparing to the research. The buyer cannot match the label dose to the dose used in the studies the ingredient is known for. Whether the product reflects the research or trades on it is not visible from the panel.
- Comparing across products. The buyer cannot meaningfully compare a transparent product to a proprietary blend product, because there is no comparable dose on one side. The shelf becomes apples-to-fog.
- Calculating total intake. The buyer taking related supplements cannot add up the daily dose of any ingredient that lives inside a blend. Underdosed supplements are one concern; doubling up on the same ingredient across products is another.
- Reading the brand. A brand that withholds dose disclosure is asking for trust without giving the option to verify. For a buyer who reads the panel carefully, that detail matters.
These verifiability costs sit on top of a baseline supplement-industry challenge. Researchers have shown unapproved drug ingredients in dietary supplements that triggered U.S. Food and Drug Administration warnings and broader patterns of supplement contamination that the current label rules have not fully closed. Proprietary blend supplements add more opacity on top of those baseline issues, and they make any single product harder for a careful buyer to judge.
Three of the four costs fall on the buyer mechanically. The fourth falls on the buyer's judgment, and for the evidence-driven consumer, it lands hardest. Supplement label transparency gives the buyer those four pieces back.
What Are the Elements of a Transparent Supplement Label?
A transparent supplement label has a small, consistent set of elements. Together, they give an informed buyer the math. The same Supplement Facts panel that permits a proprietary blend also permits a fully transparent disclosure. The format is a choice the brand makes. The regulation does not require the proprietary-blend approach.
Four elements, taken together, describe what a transparent supplement label looks like in practice.
- Each active ingredient named on the panel as a separate line item.
- Each ingredient's individual dose, disclosed in milligrams or micrograms.
- The form of each ingredient, where form affects bioavailability (how much of it your body can actually absorb). Curcumin as a standard powder is biologically different from curcumin as Meriva® Curcumin Phytosome® from Indena®. Sulforaphane from broccoli seed extract is biologically different from sulforaphane produced in the gut from glucoraphanin (a sulforaphane precursor naturally present in broccoli) with active myrosinase (the enzyme that converts it), the approach used in ingredients like Activated BroccoRaphanin Plus®.
- The dose rationale, where the brand publishes one. A brand willing to share why a particular dose was selected gives the buyer a foothold for evaluation.
A buyer who can read a label this way has the math. Underdosed supplements become easier to spot. Total daily intake across a routine becomes calculable. The label, the published research, and the buyer's own routine all sit inside the same equation. Supplement label transparency is what makes the equation solvable.
Bringing the Framework Home
This is what supplement label transparency looks like in practice. Every active ingredient named on its own line. Every dose disclosed in milligrams or micrograms. Every form specified where form affects bioavailability.
ResilienZ-12™ was built on this framework. Each of its twelve active ingredients and each dose is printed on the Supplement Facts panel, in the forms chosen for bioavailability (Meriva® Curcumin Phytosome® from Indena®, Activated BroccoRaphanin Plus® with active myrosinase, mixed tocotrienols and tocopherol) and at clinically credible, research-aligned doses set for daily, long-term use.
Studies cited above describe federal regulations, dietary patterns, and individual supplement ingredients. They do not describe the ResilienZ-12™ formula. Ingredient and dose selection in ResilienZ-12™ is informed by this research and is not equivalent to it.
Frequently Asked Questions
What is a proprietary blend in supplements?
A proprietary blend in supplements is a labeling format in which several ingredients are listed together as one mixture, with only the total weight disclosed on the panel. Individual ingredient doses are not on the label. Federal labeling rules permit the practice, and it limits what a careful buyer can verify from the panel alone.
Why do supplement companies use proprietary blends?
Supplement companies use proprietary blends for stated reasons (intellectual-property protection, formulation differentiation, competitive secrecy) and one structural reason (the flexibility to vary or under-dose individual ingredients without re-labeling). The structural reason most directly affects the buyer, because it lets a brand keep a recognizable ingredient on the panel at a token amount.
Are proprietary blend supplements bad for you?
Verifiability is the main concern with proprietary blend supplements. They are not necessarily unsafe, and most brands using them are not hiding problems. Without dose disclosure, a careful buyer cannot match the label to the research, cannot compare two products on equal terms, and cannot add up total intake across a routine.
How do I know if a supplement is underdosed?
A supplement is potentially underdosed when its label lists a familiar, well-studied ingredient inside a proprietary blend, or when the printed dose falls well below the dose used in the published research for that ingredient. Proprietary blend dosing makes the comparison impossible from the panel alone. Supplement label transparency, where every dose appears on the panel, is what makes the comparison possible.
Disclaimer:
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
Code of Federal Regulations. (current edition). 21 CFR § 101.36 — Nutrition labeling of dietary supplements. U.S. Government Publishing Office.
U.S. Food and Drug Administration. (n.d.). Dietary Supplement Labeling Guide. fda.gov.
U.S. Federal Trade Commission. (2022). Health Products Compliance Guidance. ftc.gov.
U.S. National Center for Complementary and Integrative Health. (n.d.). Coenzyme Q10. nccih.nih.gov.
Cohen, P. A. (2009). American Roulette — Contaminated dietary supplements. New England Journal of Medicine, 361(16), 1523–1525.
Cohen, P. A. (2014). Hazards of hindsight — Monitoring the safety of nutritional supplements. New England Journal of Medicine, 370(16), 1277–1280.
Mortensen, S. A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K. J., Pella, D., Alehagen, U., Steurer, G., & Littarru, G. P. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC: Heart Failure, 2(6), 641–649.
Tucker, J., Fischer, T., Upjohn, L., Mazzera, D., & Kumar, M. (2018). Unapproved pharmaceutical ingredients included in dietary supplements associated with U.S. Food and Drug Administration warnings. JAMA Network Open, 1(6), e183337.